Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
deNUC: Prezcobix and Tivicay in Virologically Suppressed HIV
NCT02499978Phase 3Withdrawn
- Sponsor
- Stanford University
- Start
- May 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of darunavir + cobicistat, dolutegravir in human immunodeficiency virus infection (HIV), sponsored by Stanford University. Planned start May 2016; status: withdrawn.
02
Drugs
darunavir + cobicistatdolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02499978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02499978.